Ausbiotech's CEO and the Australian government’s Senior Trade and Investment Commissioner in South Korea talk to Scrip on the sidelines of the Bio Korea 2022 meeting about what makes Australia an attractive clinical trial destination for Korean and other foreign pharma firms, as well as about collaborations and other opportunities between the two countries.

The Korean drug ministry has formed a commercialization strategy support group to accelerate the development of drugs and vaccines for public health crises, along with new technologies or concepts, underscoring the significance of successful development of new home-grown options.

The vice-chairman of Singapore-based Prestige Group talks to Scrip about the biopharma's strategies in Asia and elsewhere, as it focuses on vaccines for COVID-19 and other diseases, along with novel antibody therapeutics in oncology and biosimilars.

South Korea had a milestone year in terms of domestic new drug approvals in 2021, with multiple major pharma firms gaining nods for their in-house developed products, including the country’s first COVID-19 therapeutic, from Celltrion.